How Do Cancer Cells Hide from the Immune System?
How Do Cancer Cells Hide from the Immune System?
Cancer cells can hide from the immune system in several ways. They may become harder for immune cells to recognize, reduce the display of abnormal proteins, activate signals that switch down T cells, recruit immune cells that suppress attack, and change the environment around the tumor. These escape mechanisms help some cancer cells survive even when the immune system has recognized the cancer.
By Chris Morais, MSc, MPhil, PhD
- How Does the Immune System Normally Recognize Cancer Cells?
- Why Does the Immune System Not Destroy Every Cancer Cell?
- How Can Cancer Cells Become Less Visible to T Cells?
- How Do Cancer Cells Switch Off Immune Attacks?
- How Can Cancer Cells Release Signals That Weaken the Immune Response?
- How Can Cancer Recruit Immune Cells That Actually Help the Tumor?
- How Does the Tumor Environment Make It Harder for Immune Cells to Work?
- Can Cancer Cells Change Their Antigens to Escape Immune Recognition?
- Does Immune Evasion Develop as a Cancer Evolves?
- Why Can Some Cancer Cells Still Be Recognized Despite Immune Evasion?
The word “hide” is useful shorthand, but cancer cells do not make deliberate choices. Instead, cancer cells vary from one another. Cells with changes that help them survive an immune attack may remain alive and multiply, while cells that are easily recognized may be destroyed. Over time, this can make a tumor better able to escape immune control.[5]
| Immune-evasion mechanism | What happens |
|---|---|
| Reduced visibility | Cancer cells display fewer recognizable antigens or less HLA class I |
| Immune checkpoints | Inhibitory signals such as PD-1–PD-L1 reduce T-cell activity |
| Suppressive signals | Molecules such as TGF-beta and other signals weaken immune responses |
| Suppressive immune cells | Regulatory T cells and myeloid cells restrain tumor-fighting immune cells |
| Hostile tumor environment | Low oxygen, poor nutrients, acidity, and other stresses reduce immune-cell function |
| Tumor evolution | Immune attack can favor the survival of cancer cells that are harder to recognize or kill |
How Does the Immune System Normally Recognize Cancer Cells?
The immune system can recognize cancer because cancer cells often contain abnormal proteins or make normal proteins in unusual amounts or settings. Small pieces of these proteins, called antigens, can be displayed on the cancer-cell surface. T cells can inspect these displayed antigens and attack cells carrying targets they recognize.[1]
For an effective T-cell response, however, more than one step is needed. Specialized immune cells called dendritic cells can collect material from cancer cells and present cancer antigens to T cells. This helps activate T cells that recognize the tumor. Activated CD8 T cells, sometimes called cytotoxic or killer T cells, can then travel to the tumor.[1]
Cancer cells themselves display small protein fragments using molecules called MHC class I molecules. In humans, these are usually called HLA class I molecules. A CD8 T cell uses its T-cell receptor to examine the combination of an antigen fragment and an HLA class I molecule. If the T cell recognizes the antigen and receives the right supporting signals, it can kill the abnormal cell.[1]
Other parts of the immune system also take part. Natural killer cells, or NK cells, can detect some stressed or abnormal cells without recognizing one exact antigen in the same way as a T cell. This becomes especially important when a cancer cell loses HLA class I molecules.[1]
How Can Cancer Cells Display Abnormal Antigens?
Cancer cells can display abnormal antigens when genetic or other cellular changes alter the proteins they make.
One important source is a mutation in DNA. A mutation can change the amino acid sequence of a protein. When that altered protein is broken into small fragments, one of those fragments may be displayed by HLA class I molecules. If the immune system has never seen that particular fragment before, a T cell may recognize it as abnormal. Such newly formed tumor antigens are often called neoantigens.[1]
Cancer cells can also display other kinds of antigens. Some make unusually large amounts of a normal protein. Others activate genes that are usually quiet in most adult tissues. Cancers caused by viruses may also contain viral proteins that provide recognizable targets.
Not every genetic change creates an antigen that the immune system can detect. The altered protein must first be made, processed into a suitable fragment, loaded onto an appropriate HLA molecule, displayed on the cell surface, and recognized by a matching T cell. A failure at any of these steps can weaken the immune response.[1]
Why Does the Immune System Not Destroy Every Cancer Cell?
The immune system can destroy or control abnormal cells, but it cannot recognize and eliminate every cancer cell. Cancer develops from the body's own cells, so much of what is present in a cancer cell is still recognized as part of the body. Some cancers also produce few strongly abnormal antigens.
The immune system must balance two conflicting needs. It needs to attack dangerous cells, but it must also avoid attacking healthy tissues. Powerful safeguards therefore limit T-cell activation. Cancer can take advantage of those normal safeguards.[2]
Recognition alone is also not enough. A useful anti-cancer immune response requires several events to work together: antigens must be available, dendritic cells must activate suitable T cells, those T cells must reach the tumor, recognize cancer cells, remain functional, and kill enough of them.[1]
A tumor is also not made of identical cells. Different cancer cells can carry different genetic and non-genetic changes and behave differently. The immune system may destroy cells that are easy to recognize while leaving less visible cells behind.[5]
This means that immune control and cancer growth can occur at the same time. The immune system may slow or shape the cancer without completely eliminating it.[5]
How Can Cancer Cells Become Less Visible to T Cells?
Cancer cells can become less visible to T cells by interfering with the system used to display antigens. A cancer cell may still contain abnormal proteins, but those proteins are of little use to a CD8 T cell if their fragments are not presented properly on HLA class I molecules.[1]
This is an important distinction. A cancer cell does not have to remove every abnormal protein to escape recognition. Sometimes it only has to reduce the immune system's ability to see those proteins.
How Can Cancer Cells Reduce Antigen Presentation?
Cancer cells can disrupt antigen presentation at several points.
They may reduce the amount of HLA class I on their surface. They may also develop changes in genes needed to process proteins into antigen fragments or load those fragments onto HLA molecules.[1]
For example, changes affecting beta-2 microglobulin, which is needed for stable HLA class I molecules, can greatly reduce antigen presentation. Other cancers can alter proteins involved in antigen processing and transport, including the TAP proteins. Gene regulation can also reduce the expression of parts of the antigen-presentation system without permanently deleting the genes.[1]
The result is similar in each case: fewer recognizable antigen-HLA combinations appear on the cancer-cell surface, making it harder for CD8 T cells to identify the cell.
However, losing HLA class I completely can create another problem for the cancer cell. NK cells are normally restrained in part by signals from HLA class I. A cell with very little HLA class I may therefore become more vulnerable to NK-cell attack.[1]
Cancer cells must therefore survive pressure from several parts of the immune system, not just T cells.
How Do Cancer Cells Switch Off Immune Attacks?
Cancer cells can weaken an immune attack by using the body's own systems for limiting immune activity. One of the most important examples involves immune checkpoints.[2]
These pathways did not evolve for cancer. They normally protect the body from excessive or prolonged immune responses. Cancer can exploit them.
What Are Immune Checkpoints?
Immune checkpoints are molecular control systems that act as brakes on immune cells. They help prevent T cells from staying highly active for too long and damaging normal tissues.[2]
Several checkpoint pathways exist. Two of the best known involve CTLA-4 and PD-1.
CTLA-4 mainly helps control T-cell activation during the earlier stages of an immune response. PD-1 can limit the activity of T cells after they have been activated, including within tissues and tumors.[2]
These checkpoints are essential for normal immune control. The problem arises when a tumor uses the same pathways to protect itself.
This is why medicines called immune checkpoint inhibitors can work against some cancers. They do not directly kill cancer cells. Instead, they block inhibitory checkpoint pathways and can allow an existing anti-cancer immune response to act more strongly.[2]
How Can PD-L1 Help Cancer Cells Suppress T Cells?
PD-L1 is a protein that can bind to PD-1 on T cells. When PD-1 receives this signal, the T cell's activity is reduced.[2]
Some cancer cells produce high levels of PD-L1. Other cells within the tumor environment can also express it. When PD-L1 binds to PD-1 on a tumor-reactive T cell, signals inside the T cell reduce its ability to divide, release immune signals, and kill target cells.[2]
Cancer cells can increase PD-L1 for different reasons. In some cancers, internal changes in tumor signaling increase its production.
There is also a more unusual mechanism. When T cells attack a tumor, they can release a signaling protein called interferon-gamma. This is normally part of an anti-tumor immune response. But interferon-gamma can also cause nearby cancer cells to increase PD-L1. The tumor can therefore respond to an immune attack by strengthening an inhibitory pathway.[2]
PD-L1 does not make a cancer cell completely invisible. Instead, it can make T cells less effective even when they have already recognized the cancer.
How Can Cancer Cells Release Signals That Weaken the Immune Response?
Cancer cells and other cells within a tumor can release signals that make the surrounding area less favorable for an immune attack.
One important example is transforming growth factor beta, or TGF-beta. TGF-beta has normal roles in tissue repair and immune regulation, but many tumors use TGF-beta signaling to suppress anti-cancer immunity. Depending on the tumor and its surroundings, it can reduce the activity of killer T cells and NK cells, affect other immune cells, promote an immunosuppressive environment, and help exclude active T cells from parts of a tumor.[3]
Other immune-suppressing signals can include IL-10, adenosine, and substances that affect the movement or development of immune cells.
Tumors may also produce factors such as VEGF, best known for helping form new blood vessels. VEGF can influence immune cells as well as blood vessels and can contribute to an environment in which effective anti-tumor immunity is harder to maintain.
Some of these signals come directly from cancer cells. Others are produced by immune cells, fibroblasts, or other cells after the tumor changes their behavior.[3], [4]
The result is not one universal “cancer signal.” It is a network of signals that can differ greatly between cancer types and even between different areas of the same tumor.
How Can Cancer Recruit Immune Cells That Actually Help the Tumor?
Not every immune cell inside a tumor attacks cancer. Tumors can attract or promote immune-cell populations that normally limit inflammation, control tissue damage, or help repair injured tissue.[4]
Cancer can take advantage of these normal functions. Instead of supporting a strong anti-tumor response, some immune cells can suppress T cells, alter inflammation, encourage tissue remodeling, or help build conditions that support tumor survival.[4]
This is one reason why simply finding many immune cells inside a tumor does not always mean the immune system is successfully attacking it. The type and state of those immune cells matter.
How Can Regulatory T Cells and Suppressive Myeloid Cells Limit Immune Attack?
Regulatory T cells, often shortened to Tregs, normally protect the body from excessive immune responses and autoimmunity. Within many tumors, however, increased numbers or activity of Tregs can restrain anti-cancer immunity.[4]
Tregs can suppress other T cells through several mechanisms. They can use inhibitory pathways, reduce signals that other T cells need, and release immune-suppressing substances.
Another important group consists of suppressive myeloid cells. This broad group includes populations commonly called myeloid-derived suppressor cells, or MDSCs, which can build up during cancer and chronic inflammation.[4]
MDSCs can interfere with T cells in several ways. Some alter nutrients that T cells need. Others produce reactive molecules that interfere with immune-cell signaling. They can also help create and maintain an immune-suppressing tumor environment.[4]
Tumors may also contain macrophages whose activities have been altered by the local environment. Some tumor-associated macrophages can support tissue remodeling, blood-vessel formation, and immune suppression rather than an effective anti-cancer response.[4]
These immune cells are not inherently “bad.” Their normal functions are important. Cancer changes the signals around them and can turn normal immune-regulating or tissue-repair functions to its advantage.
How Does the Tumor Environment Make It Harder for Immune Cells to Work?
The tumor microenvironment is the local area surrounding cancer cells. It includes blood vessels, immune cells, fibroblasts, connective tissue, signaling molecules, nutrients, and waste products.[4]
A growing tumor can create conditions very different from those in healthy tissue.
Many solid tumors contain poorly organized blood vessels. Some regions receive too little oxygen, producing hypoxia. Blood flow may be uneven, which can also make it harder for T cells to enter all parts of the tumor.[4]
Cancer cells and other cells within tumors also alter the use and availability of nutrients. Active T cells have large energy and nutrient requirements when they divide and attack target cells. Changes in nutrient availability and the buildup of metabolic waste products can therefore interfere with immune-cell function.[4]
Tumors can produce large amounts of lactate, and parts of the tumor environment may become acidic. Low oxygen, acidity, suppressive metabolites, nutrient limitations, and other metabolic stresses can reduce the ability of T cells and NK cells to work efficiently.[4]
Physical barriers can matter as well. Fibroblasts and extracellular matrix proteins can create dense areas around some tumors. Immune cells may be present near a tumor but have difficulty reaching cancer cells in some regions.[3], [4]
Finally, T cells that encounter tumor antigens continuously for long periods can enter dysfunctional states often described as T-cell exhaustion. These cells are still present, but their ability to divide, produce signaling molecules, and kill cancer cells can decline.[4]
The tumor environment therefore affects immunity in several ways at once: it can limit immune-cell entry, expose cells to suppressive signals, create metabolic stress, and gradually weaken their function.
Can Cancer Cells Change Their Antigens to Escape Immune Recognition?
Yes. Cancer cells can sometimes escape immune attack by losing or reducing an antigen that T cells are targeting.[1], [5]
A tumor usually contains many related but genetically different cancer cells. This is called tumor heterogeneity. One group of cells may display an antigen strongly, while another group displays little of it or does not carry it at all.[5]
Suppose T cells recognize an antigen on one group of cancer cells. Those cells may be destroyed more efficiently. A second group that lacks the antigen may survive. As those surviving cells multiply, the tumor can gradually become dominated by cells that the original T-cell response does not recognize as well.[5]
An antigen can disappear for several reasons. A cancer cell may lose or change the gene that produced it. Gene regulation may switch its production down. Changes in antigen processing can also prevent the antigen from being displayed even when the underlying protein is still present.[1], [5]
This is known as antigen loss or antigen-loss escape.
The effect can be especially important when an immune response is focused strongly on one target. If the immune system recognizes several different cancer antigens, losing one target may not be enough for the cancer to escape completely.
Does Immune Evasion Develop as a Cancer Evolves?
Yes. Immune evasion can develop and change as cancer evolves.[5]
Cancer cells accumulate genetic and non-genetic differences as they divide. The immune system creates one of the pressures that determine which of those cells survive.
Cancer cells that display highly recognizable antigens may be removed. Cells that are harder to detect, better able to suppress immune cells, or more resistant to killing have a greater chance of surviving and producing new cells.[5]
This process is part of a concept called cancer immunoediting.
Immunoediting is often described in three broad phases: elimination, equilibrium, and escape.[5]
During elimination, immune responses may destroy abnormal cells before they can establish a growing cancer.
If some cancer cells survive, the immune system may continue controlling them without removing them completely. This is described as equilibrium. During this period, immune pressure can favor cancer-cell populations that are more resistant to recognition or attack.
Eventually, some surviving populations may grow despite the immune response. This is the escape phase.[5]
These phases are a useful model rather than a rigid sequence that every cancer follows. Real tumors contain many different cell populations and immune environments. Immune selection, tumor heterogeneity, and immune escape can develop together as cancers evolve.[5]
Treatment can add another form of selection. For example, an immunotherapy may remove cancer cells that remain sensitive to immune attack while resistant cells survive. This is one reason immune escape mechanisms can contribute both to initial treatment resistance and to resistance that develops later.[5]
Why Can Some Cancer Cells Still Be Recognized Despite Immune Evasion?
Immune evasion is rarely perfect. A tumor may suppress one part of the immune response while remaining vulnerable to another.
Some cancer cells continue to display recognizable antigens. Some areas of a tumor may contain active T cells even when other regions are highly suppressive. Different cancer-cell populations within the same tumor may also use different escape mechanisms.[5]
Reducing HLA class I can make a cancer cell harder for CD8 T cells to detect, for example, but very low HLA class I can make the cell more noticeable to NK cells.[1] Likewise, PD-L1 can restrain an existing T-cell response, but it does not necessarily erase the antigens those T cells recognize.[2]
This helps explain why immune cells are often found inside or around tumors even after a cancer has become established. The immune system may still recognize the cancer but be unable to overcome all of the barriers the tumor has developed.
It also explains the basic idea behind cancer immunotherapy. In some cancers, an anti-tumor immune response already exists but is being restrained. Removing an inhibitory checkpoint signal can sometimes allow that response to become more effective.[2]
Cancer immune evasion is therefore not simply a matter of cancer cells becoming invisible. Cancer cells may reduce what the immune system can see, weaken immune cells after they arrive, recruit cells that suppress them, and reshape the tumor environment. At the same time, parts of the immune system may continue recognizing and attacking the cancer.
Morais C. How Do Cancer Cells Hide from the Immune System? [Internet]. BiologyWithin.com; 2026 Sep 16. Available from: https://www.biologywithin.com/2026/09/how-cancer-cells-hide-from-immune-system.html
- Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298–312. doi:10.1038/s41568-021-00339-z.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239.
- Tauriello DVF, Sancho E, Batlle E. Overcoming TGFβ-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22:25–44. doi:10.1038/s41568-021-00413-6.
- Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat Rev Cancer. 2025;25:41–58. doi:10.1038/s41568-024-00761-z.
- Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25:353–369. doi:10.1038/s41577-024-01111-8.
Note on External Links: External links were checked and accessible when this article was published. Their content and availability may change over time and are outside the control of BiologyWithin.com.
Chris is a biologist dedicated to making complex biological and physiological sciences clear, rigorous, and accessible.
Disclaimer: This article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about personal health concerns.
Comments
Post a Comment